Tofacitinib in psoriatic arthritis
Journal
Immunotherapy
Journal Volume
9
Journal Issue
14
Pages
1153-1163
Date Issued
2017
Author(s)
Wang T.-S.
Abstract
Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. We reviewed the evidences of tofacitinib in psoriatic arthritis treatment. The efficacy and safety profiles result from Phase III clinical trials (OPAL BROADEN and OPAL BEYOND) and one open-label extension study (OPAL BALANCE). Both tofacitinib 5 or 10 mg twice a day were superior to placebo for American College of Rheumatology 20% improvement criteria response at 3 months and showed significant improvement of skin, enthesitis and dactylitis. Tofacitinib is a promising treatment option for psoriatic arthritis. ? 2017 2017 Future Medicine Ltd.
SDGs
Other Subjects
tofacitinib; Janus kinase; piperidine derivative; protein kinase inhibitor; pyrimidine derivative; pyrrole derivative; tofacitinib; Article; cerebrovascular accident; dactylitis; digestive system perforation; drug efficacy; drug fatality; drug safety; drug tolerability; enthesitis; evidence based practice; general condition improvement; headache; health care management; heart infarction; herpes zoster; human; inflammatory bowel disease; parotitis; pharmacological parameters; pneumonia; priority journal; psoriatic arthritis; pyonephrosis; rheumatology; rhinopharyngitis; therapy effect; thrush; upper respiratory tract infection; uveitis; animal; antagonists and inhibitors; clinical trial (topic); psoriasis; psoriatic arthritis; Animals; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles
Publisher
Future Medicine Ltd.
Type
journal article